New insights in the pathophysiology of preeclampsia and potential therapeutic implications;Avancées récentes dans la compréhension de la physiopathologie de la prééclampsie et conséquences thérapeutiques potentielles

Nephrologie et Therapeutique

Volumn 3, Issue 7, 2007, Pages 437-448

  Boulanger, Henri ^a,b   Flamant, Martin ^b  

^a Centre de néphrologie et de dialyse de la clinique de l'Estree   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Placental growth factor; Preeclampsia; Soluble endoglin; Soluble fms like tyrosine kinase 1; Transforming growth factor beta; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II; ARGININE DERIVATIVE; BLOOD CLOTTING FACTOR 5; CYTOKINE; DIMETHYLARGININE; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INTERLEUKIN 1; NEUROKININ; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

AMENORRHEA; ANGIOGENESIS; CHROMOSOME 10; ENDOTHELIAL DYSFUNCTION; GENE LOCUS; GENETICS; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREECLAMPSIA; PREGNANCY; RENDU OSLER WEBER DISEASE; REPRODUCTION; RISK FACTOR; SHORT SURVEY; SYNCYTIOTROPHOBLAST;

ANTIGENS, CD; BIOLOGICAL MARKERS; CYTOKINES; ECLAMPSIA; ENDOTHELIUM, VASCULAR; FEMALE; HELLP SYNDROME; HUMANS; ISCHEMIA; KIDNEY GLOMERULUS; NEOVASCULARIZATION, PATHOLOGIC; PLACENTA; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; RECEPTORS, ANGIOTENSIN; RECEPTORS, CELL SURFACE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 36348979230     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2007.07.001     Document Type: Short Survey

References (56)

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 183 (2000) S1-S20
2. Oudejans C.B., van Dijk M., Oosterkamp M., Lachmeijer A., and Blankenstein M.A. Genetics of preeclampsia: paradigm shift. Hum. Genet. 120 (2007) 607-612
3. Redman C.W., and Sargent I.L. Latest advances in anderstanding preeclampsia. Science 308 (2005) 1592-1594
4. Egbor M., Ansari T., Morris N., Green C.J., and Sibbons P.D. Morphometric placental villous and vascular abnormalities in early and late onset preeclampsia with and without fetal growth restriction. BJOG 113 (2006) 580-589
5. Skjaerven R., Vatten L.J., Wilcox A.J., Ronning T., Irgens L.M., and Lie R.T. Recurrence of preeclampsia across generations exploring feta land maternal genetic components in a population based cohort. BMJ 331 (2005) 877-882
6. Sibai B.M., Ewell M., Levine R.J., Klebanoff M.A., Esterlitz J., Catalono P.M., et al. Risk factors associated with preeclampsia in healthy nulliparous women. Am. J. Obstet. Gynecol. 177 (1997) 1003-1010
7. Bodnar L.M., Catov J.M., Klebanoff M.A., Ness R.B., and Roberts J.M. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology 18 (2007) 234-239
8. Duckitt K., and Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ 330 (2005) 565-572
9. Mello G., Paretti E., Marozio L., Pizzi C., Lojacono A., Frusca T., et al. Thrombophilia is significantly associated with severe preeclamspia. Result of a large scale, care controlled study. Hypertension 46 (2005) 1270-1274
10. Rey E., Kahn S.R., David M., and Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 (2003) 901-908
11. Lin J., and August P. Genetic thrombophilias and preeclampsia: a meta analysis. Obstet. Gynecol. 105 (2005) 182-192
12. The GOPEC Consortium. Disentangling fetal and maternal susceptibility for preeclampsia: a british multicenter candidate-gene study. Am. J. Hum. Genet. 77 (2005) 127-131
13. Ward K., Hata A., Jeunemaitre X., Helin C., Nelson L., Namikawa C., et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat. Genet. 4 (1993) 59-61
14. Morgan L., Baker P., Broughton Pipkin F., and Kalsheker N. Preclampsia and the angiotensinogen gene. Br. J. Obstet. Gynaecol. 102 (1995) 489-490
15. Arngrimsson R., Hayward C., Nadaud S., Baldursdottir A., Walker J.J., Liston W.A., et al. Evidence for a familial pregnancy-induced hypertension locus in the e NOS-gene region. Am. J. Hum. Genet. 61 (1997) 354-362
16. Arngrimson R., Siguroardottir S., Frigge M.L., Bjanadottir R.I., Jonsson T., Stefansson H., et al. A genome-wide scan reveals a maternal susceptibility locus for preeclampsia on chromosome 2p13. Hum. Mol. Genet. 8 (1999) 1799-1805
17. Laivuori H., Lahermo P., Ollikainen V., Widen E., Haivan-Mallinen L., Sundstrom H., et al. Susceptibility loci for preeclampsia on chromosomes 2p25 et 9p13 in Finnish families. Am. J. Hum. Genet. 72 (2003) 168-177
18. Van Dijk M., Mulders J., Poutsma A., Könst A.A., Lachmeijer A., Dekker G.A., et al. Maternal segregation of the dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat. Genet. 37 (2005) 514-519
19. Le Bouteiller P., and Tabiasco J. Immunology of pregnancy: renewed interest. Med. Sci. (Paris) 22 (2006) 745-750
20. Hiby S.E., Walker J.J., O'shaughnessy K.M., Redman C.W., Carrington M., Trowsdale J., et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 18 (2004) 957-965
21. Abitbol M.M., Ober W.B., Gallo G.R., Driscoll S.G., and Pirani C.L. Experimental toxemia of pregnancy in the monkey, with a preliminary report of renin aldosterone. Am. J. Pathol. 86 (1977) 573-583
22. Combs C.A., Katz M.A., Kitzmiller J.L., and Brescia R.J. Experimental preeclampsia produced by chronic constriction of the aorta in conscious rhesus monkey. Am. J. Obstet. Gynecol. 169 (1993) 121-123
23. Makris A., Thornton C., Thompson J., Thomson S., Martin R., Ogle R., et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71 (2007) 977-984
24. Zhou Y., Fisher S.J., Janatpour M., Genbacev O., Dejana E., Wheelock M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J. Clin. Invest. 99 (1997) 2139-2151
25. Zhou Y., Damsky C.H., and Fischer S.J. Preclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J. Clin. Invest. 99 (2000) 2152-2163
26. Davidson J.M., Homult V., Jeyabalan A., Conrad K.P., Karumanchi S.A., Quaggin S., et al. New aspects in the pathophysiology of preeclampsia. J. Am. Soc. Nephrol. 15 (2004) 2440-2448
27. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., and Mc Laughin M.K. Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 161 (1989) 1200-1204
28. Ness R.B., and Roberts J.M. Heterogeneous causes constituting the single syndrome of preeclampsia: an hypothesis and its implications. Am. J. Obstet. Gynecol. 175 (1996) 1365-1370
29. Page M.N., Woods R.J., Gardiner S.M., Lomthaisong K., Gladwell R.T., Butlin D.J., et al. Excessive placental secretion of neurokinin B during the third trimester causes preeclampsia. Nature 15 (2000) 787-800
30. Redman C.W.G., and Sargent I.L. Preeclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta 24 (2003) S21-SS7
31. Savvidou M.D., Hingorani A.D., Tsikas D., Frolich J.C., Vallance P., and Nicolaides K.H. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia. Lancet 361 (2003) 1511-1517
32. Molnar M., Suto T., Toth T., and Hertelendy F. Prolonged blockage of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am. J. Obstet. Gynecol. 170 (1994) 1458-1466
33. Wallukat G., Homuth V., Fisher T., Lindschau C., Horstkamp B., Jupner A., et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103 (1999) 945-952
34. Maynard S.E., Min J.-Y., Merchan J., Lim K., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111 (2003) 649-658
35. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., et al. Soluble endogline contributes to the pathogenesis of preeclampsia. Nat. Med. 12 (2006) 642-651
36. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
37. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metatastatique colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
38. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111 (2003) 707-716
39. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350 (2004) 672-683
40. Hertig A., Berkane N., Lefevre G., Toumi K., Mart H.P., Capeau J., et al. Maternal serum sFlt-1 concentration is an early and reliable predictive marker of preeclampsia. Clin. Chem. 50 (2004) 1702-1703
41. Strevens H., Wide-Swensson D., Hansen A., Horn T., Ingermarsson I., Larsen S., et al. Glomerular endotheliosis in normal pregnancy and preeclampsia. BJOG 110 (2003) 831-836
42. Tuohy J.F., and James D.K. Preeclampsia and trisomy 13. Br. J. Obstet. Gynaecol. 99 (1992) 891-894
43. Bdolah Y., Palomaki G.E., Yaron Y., Bdolah-Abraham T., Goldman M., Levine R.J., et al. Circulating angiogenic proteins in trisomy 13. Am. J. Obstet. Gynecol. 194 (2006) 239-245
44. Powers R.W., Roberts J.M., Cooper K.M., Gallaher M.J., Frank M.P., Harger G.F., et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am. J. Obstet. Gynecol. 193 (2005) 185-191
45. Zacchigna L., Vecchione C., Notte A., Cordenonsi M., Dupont S., Maretto S., et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 124 (2006) 929-942
46. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., et al. Soluble endogline and other anti-angiogenic factors in preeclampsia. N. Engl. J. Med. 355 (2006) 992-1005
47. Zhou Y., McMaster M., Woo K., Janatpour M., Perry J., Karpanen T., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelet syndrome. Am. J. Pathol. 160 (2002) 1405-1423
48. Ahmad S., and Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95 (2004) 884-891
49. Nagamatsu T., Fujii T., Kusumi M., Zou L., Yamashita T., Osuga Y., et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145 (2004) 4838-4845
50. Hornig C., Barleon B., Ahmad S., Vuorela P., Ahmed A., and Weich H.A. Release and complex formation of soluble VEGF-1 from endothelial and biological fluids. Lab. Invest. 80 (2000) 443-454
51. Karumanchi S.A., and Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken and egg" question. Endocrinology 145 (2004) 4835-4837
52. Chaiworapongsa T., Romero R., Espinoza J., Bujold E., Mee Kim Y., et al. Evidence supporting a role for blockage of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: young investigator award. Am. J. Obstet. Gynecol. 190 (2004) 1541-1547
53. Shibata E., Rajakumar A., Powers R.W., Larkin R.W., Gilmour C., Bodnar L.M., et al. Soluble fms like tyrosine kinase 1 (sFlt-1) is increased in preeclampsia but not in normotensive pregnancies with small for gestational age neonates: relationship to circulating placental growth factor (PlGF). J. Clin. Endocrinol. Metab. 90 (2005) 4895-4903
54. Levine R.J., Thadhani R., Qian C., Lam C., Lim K.H., Yu K.F., et al. Urinary placental growth factor and risk of preeclampsia. JAMA 293 (2005) 77-85
55. Levine R.J., Hauth J.C., Curet L.B., Sibai B.M., Catalano P.M., and Morris C.D. Trial of calcium to prevent preeclampsia. N. Engl. J. Med. 337 (1997) 69-76
56. Zhihe L., Zhang Y., Qiming S., et al. Recombinant vascular endothelial growth factor-123 attenuates hypertension in pregnant rats overproducing soluble fms-like tyrosine kinase-1 gene. Hypertension Preg 25 suppl 1 (2006) 51 [abstract]